Effect of Atorvastatin in patients with Rheumatoid Arthritis

INTERVENTION: Atorvastatin with a dose of 40 mg once daily during 8 weeks in intervention group Intervention 1: Atorvastatin with a dose of 40 mg once daily during 8 weeks in intervention group. Intervention 2: Placebo once daily during 8 weeks in control group. Placebo Placebo once daily during 8 weeks in control group Treatment ‐ Drugs CONDITION: Rheumatoid Arthritis. ; seropositive rheumatoid arthritis seropositive rheumatoid arthritis PRIMARY OUTCOME: CRP : C Reactive Protein. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: Proportional Scale by blood sampling. DAS28 Score. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: Standard DAS28 Questionnarie. ESR : Erythrocyte Sedimentation Rate. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: mm/h and by Western Green Method. Swelling Joint Count (SJC). Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: numerical Scale and by examination of physician. Tender Joint Count (TJC). Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: numerical Scale and by examination of physician. SECONDARY OUTCOME: Myopathy. Timepoint: 3 weeks after beginning of study and after it during the study. Method of measurement: through history and question about muscular pain. INCLUSION CRITERIA: Inclusion Criteria : 1‐ Patients with Rheumatoid Arthritis basis on ACR2010 Criteria and with moderate to sever disease activity with DAS28 Score Exclusion Criteria : 1‐ age under 18 years old 2‐ disease duration more than 5 years 3‐ present use of Atorvastatin 4‐Contraindication of Atorvastatin use consist of Hepatic or Renal failure 5‐ presence of each kind of cancer 6‐ Pregnancy